NEW STRATEGIES TO PREVENT STAPHYLOCOCCUS-AUREUS INFECTIONS IN PERITONEAL-DIALYSIS PATIENTS

Citation
A. Vychytil et al., NEW STRATEGIES TO PREVENT STAPHYLOCOCCUS-AUREUS INFECTIONS IN PERITONEAL-DIALYSIS PATIENTS, Journal of the American Society of Nephrology, 9(4), 1998, pp. 669-676
Citations number
64
Categorie Soggetti
Urology & Nephrology
ISSN journal
10466673
Volume
9
Issue
4
Year of publication
1998
Pages
669 - 676
Database
ISI
SICI code
1046-6673(1998)9:4<669:NSTPSI>2.0.ZU;2-R
Abstract
The importance of Staphylococcus aureus as etiological agent for cathe ter-related infections and peritonitis in peritoneal dialysis patients is well established. To evaluate groups at risk of developing Staphyl ococcus aureus infections, nasal and exit-site cultures were performed in 76 peritoneal dialysis patients monthly over a period of 3 yr. The risk of Staphylococcus aureus catheter infection was significantly hi gher in diabetic (group 1) and immunosuppressed (group 2) patients com pared with nondiabetic and nonimmunosuppressed (group 3) patients. In diabetic patients, Staphylococcus aureus-positive nasal cultures were more frequent than positive cultures taken from the bland exit-site (7 3.3% versus 60.0%). On the other hand, both positive and negative exit -site cultures had a better prognostic value for Staphylococcus aureus catheter infection compared with nasal cultures. In immunosuppressed patients, both nasal and exit-site carriages were associated with a ve ry high risk of Staphylococcus aureus catheter infection, but nasal sw abs were far more often positive than swabs from the bland exit-site ( 72.7% versus 25.0%). However, the risk of infection was also high for non-nasal and non-exit-site carriers in this group. In nondiabetic and nonimmunosuppressed patients, the risk of Staphylococcus aureus cathe ter infection was increased only if two or more positive nasal culture s were detected, It is concluded that in diabetic patients, antibiotic prophylaxis should be performed in all Staphylococcus aureus exit-sit e carriers. All immunosuppressed patients should be treated prophylact ically. In contrast, in nondiabetic and nonimmunosuppressed patients, prophylactic treatment should be considered only in nasal carriers wit h two or more positive cultures. The overall low peritonitis rate does not influence this prevention strategy.